PRESS-NEWS.org - Press Release Distribution
PRESS RELEASES DISTRIBUTION

PacketMicro Announces an FCC-Certified ZigBee Module Based on TI CC2530

New ZigBee module with FCC modular approval significantly reduces product development time and costs.

2010-09-30
SANTA CLARA, CA, September 30, 2010 (Press-News.org) PacketMicro announces today that it is offering an FCC-certified ZigBee module based on the TI CC2530 chip to the US market. The high-performance, low-cost GFZM-T5321 module is one of the key components of PacketMicro engineering services in the wireless sensor networks (WSN) and radio frequency identification (RFID) areas.

"Wireless ZigBee technology offers the best combination of low power, small form factor, and ease of implementation," said Dr. Richard Zai, PacketMicro Chief Technology Officer. "Combining the ZigBee module and sensors helps solve many real-life problems by remotely monitoring or controlling the changes in temperature, pressure, acceleration, toxic gas level, speed, or other physical elements. ZigBee wireless sensor network can be deployed in many environments easily because of its unique and simple mesh-networking capability."

The GFZM-T5321 ZigBee module is the first PacketMicro offering of a series of wireless building blocks, including the battery-assisted passive (BAP) tags, combo tags (ZigBee and BAP), UHF passive RFID module, GSM modules, and WiMax 16d module for remote sensing, asset-tracking, and healthcare monitoring applications.

About PacketMicro
PacketMicro, based in Silicon Valley, offers world-class designs in the wireless sensor networks and radio frequency identification areas. It provides one-stop engineering services, including FCC certified wireless subsystems, to help its customers shorten their product development cycles. PacketMicro also provides design services in the FPGA and signal integrity areas. For more information, please visit www.packetmicro.com.


ELSE PRESS RELEASES FROM THIS DATE:

Temptations Parties Celebrates 10th Anniversary

Temptations Parties Celebrates 10th Anniversary
2010-09-30
For the past 10 years, Temptations Parties has focused on "Keeping America Happy" by providing romance education and romance enhancement concepts from a sex positive perspective in an entertaining and discreet atmosphere. With male and female independent distributors, Temptations Parties continues to grow throughout a vast majority of the United States as well as US territories. At a Temptations Party the Romance Consultant appeals to the guests' senses, creating the ability to see, smell, taste and touch our products. In addition, party guests are able to place their orders ...

Houston Janitorial Services Creates World Class Training System

2010-09-30
Houston Janitorial Services has done it again. Based on the industry's first Tier One Safety system, Houston Janitorial has ramped up its service processes again. With focus on safety firmly established, janitorial service process training has taken place with service-level staff. The safety program is called the Tier One Safety System. This system gives facility owners the assurance that the staff in their buildings have the highest regard for safe activity. The Tier One Safety System has now been enhanced by adding the new Quality Cleaning Process for commercial ...

Find New Customers Announces Webinar Series on B2B Marketing and Demand Generation

2010-09-30
With sales quota achievement at an all-time low and the worst economic downturn in memory, Find New Customers, a B2B sales and marketing automation consultancy, announces a series of webinars with top B2B marketing thought leaders. The "B2B Demand Generation Thought Leadership Series" is designed to help B2B companies develop the strategies and tactics necessary to increase sales-ready leads and close more business. The lineup of B2B marketing experts will be announced in early October. More information about the webinar series can be found at http://www.FindNewCustomers.com/B2B-webinar. Paige ...

Guide to Natural Eczema Treatments Hits the Market - From Eczema Free Forever TM

Guide to Natural Eczema Treatments Hits the Market - From Eczema Free Forever TM
2010-09-30
Eczema Free Forever TM provides answers to practical, homemade and natural solutions, that the eczema suffering population in any part of the world can easily perform in the comfort of their home. One in eight people suffer from eczema in the U.S. That's 15 million people. What causes eczema? Which eczema treatment works best? These are questions that the millions of people with the condition ask regularly. There certainly is no shortage of medicines available on the market that lay claim to being the absolute best cure for eczema. The creams and oily goop that pass ...

Triple-negative breast cancers may have unique therapeutic target

2010-09-29
DENVER — Patients with triple-negative breast cancer, one of the hardest subtypes to treat, may have a unique biomarker that would enable them to receive more targeted therapy, according to data presented at the Fourth AACR International Conference on Molecular Diagnostics in Cancer Therapeutic Development. Triple-negative breast cancers are breast cancers that have tested negative for estrogen receptors, progesterone receptors and HER2. Because of this biology, these cancers do not respond to endocrine therapies or trastuzumab. "In other subsets of breast cancer, ...

Circulating tumor cells can provide 'real-time' information on patient's current disease state

2010-09-29
DENVER — Circulating tumor cells (CTCs) may be a promising alternative, noninvasive source of tumor materials for biomarker assessment, according to data presented at the Fourth AACR International Conference on Molecular Diagnostics in Cancer Therapeutic Development. "The basic idea is that CTCs can provide real-time information about a patient's current disease state, acting as a 'liquid biopsy,'" said Siminder Kaur Atwal, Ph.D., senior research associate at Genentech. "They are much less invasive than tumor biopsies because they can be detected from a blood draw and ...

Biomarker panel identifies prostate cancer with 90 percent accuracy

2010-09-29
DENVER — Researchers in England say they have discovered a set of biomarkers that can distinguish prostate cancer from benign prostate disease and healthy tissue with 90 percent accuracy. This preliminary data, if validated in larger ongoing studies, could be developed into a serum protein test that reduces the number of unnecessary biopsies and identifies men who need treatment before symptoms begin. The researchers, from Oxford Gene Technology (OGT) and its subsidiary, Sense Proteomic, Ltd., presented their findings at the Fourth AACR International Conference on Molecular ...

New biomarkers discovered for pancreatic cancer and mesothelioma

2010-09-29
DENVER — Using a novel aptamer-based proteomics array technology, researchers and collaborators have identified biomarkers and protein signatures that are hallmarks of cancer at an early stage for two of the most aggressive and deadly forms of cancer — pancreatic and mesothelioma. This technology would enable better clinical diagnosis at an earlier stage and may provide insight into new therapeutic targets, said Rachel Ostroff, Ph.D., clinical research director of Somalogic Inc. "Currently these cancers are detected at an advanced stage, where the possibility of cure ...

African-Americans equally likely to benefit from erlotinib and other targeted lung cancer therapy

2010-09-29
DENVER — African-American patients with non-small cell lung cancer are just as likely to display an epidermal growth factor receptor (EGFR) mutation in tumors as Caucasians, which suggests they are as likely to benefit from targeted therapies such as erlotinib. "This study has immediate implications for patient management. Patients with EGFR mutations have a much better prognosis and respond better to erlotinib than those who do not," said Ramsi Haddad, Ph.D., director of the Laboratory of Translational Oncogenomics at the Barbara Ann Karmanos Cancer Institute, and assistant ...

Novel biomarker may predict response to new VEGF receptor inhibitor

2010-09-29
DENVER — Researchers believe there may be a way to predict, based on individual tumors, those patients that are more likely to respond to the investigational new drug tivozanib. This is possible, the researchers from AVEO Pharmaceuticals, Inc. said, because they have used a new way of creating animal tumor models that mimic tumor variation seen in human. Based on the results of these studies, they have found a single biomarker that may predict resistance to tivozanib, an oral, triple VEGF (vascular endothelial growth factor) receptor inhibitor. Tivozanib is in an ...

LAST 30 PRESS RELEASES:

Rugged Falklands landscape was once a lush rainforest

Dizziness in older adults is linked to higher risk of future falls

Triptans more effective than newer, more expensive migraine drugs

Iron given through the vein corrects iron deficiency anaemia in pregnant women faster and better than iron taken by mouth

The Lancet Neurology: Air pollution, high temperatures, and metabolic risk factors driving global increases in stroke, with latest figures estimating 12 million cases and over 7 million deaths from st

Incidence of neuroleptic malignant syndrome during antipsychotic treatment in children and youth

Levels of protection from different cycle helmets revealed by new ratings

Pupils with SEND continue to fall behind their peers

Half of heavier drinkers say calorie labels on alcohol would lead to a change in their drinking habits

Study first to link operating room design to shorter surgery

New study uncovers therapeutic inertia in the treatment of women with multiple sclerosis

Cancer Cooperative Group leaders propose a re-engineering of the nation’s correlative science program for cancer

Nawaz named ASME Fellow

U2opia signs license to commercialize anomaly-detection technology for cybersecurity

Explaining dramatic planetwide changes after world’s last ‘Snowball Earth’ event

Cleveland Clinic study is first to show success in treating rare blood disorder

Bone marrow cancer drug shows success in treatment of rare blood disorder

Clinical trial successfully repurposes cancer drug for hereditary bleeding disorder

UVA Engineering professor awarded $1.6M EPA grant to reduce PFAS accumulation in crops

UVA professor receives OpenAI grant to inform next-generation AI systems

New website helps researchers overcome peer reviewers’ preference for animal experiments

Can the MIND diet lower the risk of memory problems later in life?

Some diabetes drugs tied to lower risk of dementia, Parkinson’s disease

Propagated corals reveal increased resistance to bleaching across the Caribbean during the fatal heatwave of 2023

South African rock art possibly inspired by long-extinct species

Even marine animals in untouched habitats are at risk from human impacts

Hexagonal electrohydraulic modules shape-shift into versatile robots

Flexible circuits made with silk and graphene on the horizon

Scott Emr and Wesley Sundquist awarded 2024 Horwitz Prize for discovering the ESCRT pathway

Versatile knee exo for safer lifting

[Press-News.org] PacketMicro Announces an FCC-Certified ZigBee Module Based on TI CC2530
New ZigBee module with FCC modular approval significantly reduces product development time and costs.